TN2011000207A1 - Akt and p70 s6 kinase inhibitors - Google Patents

Akt and p70 s6 kinase inhibitors

Info

Publication number
TN2011000207A1
TN2011000207A1 TN2011000207A TN2011000207A TN2011000207A1 TN 2011000207 A1 TN2011000207 A1 TN 2011000207A1 TN 2011000207 A TN2011000207 A TN 2011000207A TN 2011000207 A TN2011000207 A TN 2011000207A TN 2011000207 A1 TN2011000207 A1 TN 2011000207A1
Authority
TN
Tunisia
Prior art keywords
akt
kinase inhibitors
formula
compounds
present
Prior art date
Application number
TN2011000207A
Other languages
English (en)
Inventor
Robert Dean Dally
Sajan Joseph
Timothy Alan Shepherd
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TN2011000207A1 publication Critical patent/TN2011000207A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TN2011000207A 2008-11-11 2011-04-25 Akt and p70 s6 kinase inhibitors TN2011000207A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11327308P 2008-11-11 2008-11-11
PCT/US2009/063020 WO2010056563A1 (fr) 2008-11-11 2009-11-03 Inhibiteurs de kinase akt et p70 s6

Publications (1)

Publication Number Publication Date
TN2011000207A1 true TN2011000207A1 (en) 2012-12-17

Family

ID=41402451

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000207A TN2011000207A1 (en) 2008-11-11 2011-04-25 Akt and p70 s6 kinase inhibitors

Country Status (37)

Country Link
US (1) US8148387B2 (fr)
EP (1) EP2358710B1 (fr)
JP (1) JP5432275B2 (fr)
KR (1) KR101334460B1 (fr)
CN (1) CN102216302B (fr)
AR (1) AR074072A1 (fr)
AU (1) AU2009314324B2 (fr)
BR (1) BRPI0921916A2 (fr)
CA (1) CA2743019C (fr)
CO (1) CO6382114A2 (fr)
CR (1) CR20110240A (fr)
CY (1) CY1113409T1 (fr)
DK (1) DK2358710T3 (fr)
DO (1) DOP2011000129A (fr)
EA (1) EA018947B1 (fr)
EC (1) ECSP11011048A (fr)
ES (1) ES2391704T3 (fr)
HK (1) HK1158203A1 (fr)
HN (1) HN2011001247A (fr)
HR (1) HRP20120738T1 (fr)
IL (1) IL211940A (fr)
JO (1) JO2822B1 (fr)
MA (1) MA32776B1 (fr)
MX (1) MX2011005000A (fr)
MY (1) MY161461A (fr)
NZ (1) NZ592062A (fr)
PA (1) PA8846901A1 (fr)
PE (1) PE20110807A1 (fr)
PL (1) PL2358710T3 (fr)
PT (1) PT2358710E (fr)
RS (1) RS52520B (fr)
SI (1) SI2358710T1 (fr)
TN (1) TN2011000207A1 (fr)
TW (1) TWI422587B (fr)
UA (1) UA100190C2 (fr)
WO (1) WO2010056563A1 (fr)
ZA (1) ZA201102549B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120106714A (ko) 2009-07-02 2012-09-26 사노피 신규 (6-옥소-1,6-디히드로-피리미딘-2-일)아미드 유도체, 그의 제조법, 및 ａｋｔ(ｐｋｂ) 인산화 억제제로서의 그의 제약 용도
EP2491032B1 (fr) * 2009-10-23 2014-04-16 Eli Lilly and Company Inhibiteurs d'akt
HUE026323T2 (en) 2011-04-07 2016-05-30 Bayer Ip Gmbh Imidazopyridazines as AKT kinase inhibitors
WO2013007167A1 (fr) * 2011-07-09 2013-01-17 山东轩竹医药科技有限公司 Forme cristalline i d'un sel d'un inhibiteur de dipeptidyl-peptidase-iv, son procédé de préparation et son utilisation
SI2755958T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti
MX346095B (es) * 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
AU2013344552B2 (en) * 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
CN105102435A (zh) 2012-11-16 2015-11-25 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
KR20150124957A (ko) * 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
BR112016015285A8 (pt) * 2014-02-11 2020-06-09 Merck Patent Gmbh pirimidina imidazol aminas como moduladores da atividade de quinase, seus usos e seu processo de preparação, composição farmacêutica, e kit
TW201718574A (zh) 2015-08-12 2017-06-01 美國禮來大藥廠 Ｃｇｒｐ受體拮抗劑
TWI732187B (zh) * 2016-05-20 2021-07-01 日商大鵬藥品工業股份有限公司 新穎5H-吡咯并[2, 3-d]嘧啶-6(7H)-酮衍生物
BR112022017856A2 (pt) * 2020-03-17 2022-11-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado bicíclico fundido, método de preparação do mesmo e uso farmacêutico do mesmo
CN113444110B (zh) * 2020-03-25 2023-05-12 江苏恒瑞医药股份有限公司 四氢吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
CA3231865A1 (fr) 2021-09-17 2023-03-23 Tingting SHANG Derive bicyclique fusionne, sel pharmaceutiquement acceptable, forme cristalline de celui-ci et son procede de preparation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563699C (fr) 2004-04-23 2014-03-25 Exelixis, Inc. Modulateurs de kinase et methode d'utilisation
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
US7423043B2 (en) * 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
JP5114395B2 (ja) 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
EP2043655A2 (fr) 2006-04-25 2009-04-08 Astex Therapeutics Limited Derives de purine et de deazapurine comme composes pharmaceutiques
EP2037931A2 (fr) 2006-04-25 2009-03-25 Astex Therapeutics Limited Combinaisons pharmaceutiques contenant des inhibiteurs du pk et des autres agents actifs
WO2008012635A2 (fr) 2006-07-26 2008-01-31 Pfizer Products Inc. Dérivés d'amines utiles en tant qu'agents anticancéreux
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
JP2012508274A (ja) 2012-04-05
AU2009314324B2 (en) 2013-06-20
CA2743019C (fr) 2013-08-13
PT2358710E (pt) 2012-10-01
ECSP11011048A (es) 2011-06-30
PL2358710T3 (pl) 2012-12-31
EP2358710A1 (fr) 2011-08-24
CR20110240A (es) 2011-06-09
JO2822B1 (en) 2014-09-15
EP2358710B1 (fr) 2012-08-15
DOP2011000129A (es) 2016-02-29
EA201170680A1 (ru) 2011-12-30
JP5432275B2 (ja) 2014-03-05
HN2011001247A (es) 2013-05-20
ES2391704T3 (es) 2012-11-29
CA2743019A1 (fr) 2010-05-20
EA018947B1 (ru) 2013-11-29
CO6382114A2 (es) 2012-02-15
AU2009314324A1 (en) 2010-05-20
UA100190C2 (en) 2012-11-26
MY161461A (en) 2017-04-14
BRPI0921916A2 (pt) 2015-12-29
NZ592062A (en) 2013-03-28
AR074072A1 (es) 2010-12-22
MX2011005000A (es) 2011-05-25
IL211940A (en) 2014-01-30
CY1113409T1 (el) 2016-06-22
CN102216302A (zh) 2011-10-12
TW201022268A (en) 2010-06-16
RS52520B (en) 2013-04-30
PA8846901A1 (es) 2010-06-28
US20100120801A1 (en) 2010-05-13
SI2358710T1 (sl) 2012-11-30
KR20110074578A (ko) 2011-06-30
DK2358710T3 (da) 2012-09-03
HK1158203A1 (en) 2012-07-13
PE20110807A1 (es) 2011-10-31
KR101334460B1 (ko) 2013-12-02
US8148387B2 (en) 2012-04-03
HRP20120738T1 (hr) 2012-10-31
TWI422587B (zh) 2014-01-11
WO2010056563A1 (fr) 2010-05-20
ZA201102549B (en) 2012-09-26
IL211940A0 (en) 2011-06-30
MA32776B1 (fr) 2011-11-01
CN102216302B (zh) 2013-08-21

Similar Documents

Publication Publication Date Title
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
MY154898A (en) P70 s6 kinase inhibitors
SG179085A1 (en) Pi3 kinase inhibitors and uses thereof
PH12015501484A1 (en) Heteroaryl compounds and uses thereof
MX2012004780A (es) Inhibidores de akt.
TW201713640A (en) Bruton's tyrosine kinase inhibitors
MY153915A (en) Organic compounds
MY148634A (en) Pyridazinone derivatives
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
MY181898A (en) Heterocyclic compounds and uses thereof
MY146989A (en) Kinase inhibitors
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
MX2010006738A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
MX2010006736A (es) Inhibidores de proteasa del virus de la hepatitis c (hcv) y usos de los mismos.
TN2010000131A1 (en) Polo-like kinase inhibitors
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
WO2012122383A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
TNSN08191A1 (en) Kinase inhibitors
UA85505C2 (en) Kinase inhibitors
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
WO2010077730A3 (fr) Inhibiteurs indanones de l'acétylcholinestérase
WO2010059639A3 (fr) Inhibiteurs à base d'hydroxyadamantyle de dipeptidylpeptidase iv
WO2009114856A3 (fr) Inhibiteurs des aurora kinases